Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, raised $14 million by offering 1.5 million ADSs at $9.21. Each ADS was sold with one third of a warrant to purchase an ADS at a $5.50 exercise price. The company's ordinary shares trade on the Australian Stock Exchange under the ticker BLT. Benitec had originally planned to raise $65 million by offering 5 million ADSs but cut its deal and added warrants last week.
Benitec will list on the Nasdaq under the symbol BNTC. Maxim Group acted as sole bookrunner on the deal. Just Read More Dig this: SiteOne Landscape Supply files for a $100 million IPO
Blogger Comment
Facebook Comment